SCHEMBL5137973

SCHEMBL5137973

CCCCN(Cc1ccc(OC)c(C)c1OC)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
MAPT P10636 1/20 0.41
BCHE P06276 7/20 0.38
C5AR1 P21730 1/20 0.37
CASR P41180 1/20 0.36
GAA P10253 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DRD2 P14416 4/20 0.34
DRD3 P35462 4/20 0.34
DRD1 P21728 3/20 0.34
DRD4 P21917 3/20 0.34
HTR2C P28335 2/20 0.34
TSHR P16473 1/20 0.34
MAPK14 Q16539 1/20 0.33
ACHE P22303 1/20 0.33
DRD5 P21918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136445 0.93 DRD2 (0.38) TP53BCHEC5AR1CASRGAA
SCHEMBL5138090 0.92 TP53 (0.40) TP53BCHEC5AR1GAASMN1; SMN2
SCHEMBL5137642 0.92 POLB (0.37) TP53MAPTC5AR1CASRGAA
SCHEMBL5137367 0.92 KDM4E (0.37) TP53MAPTBCHEC5AR1GAA
SCHEMBL5135326 0.90 C5AR1 (0.36) TP53BCHEC5AR1CASRGAA
SCHEMBL5137330 0.87 BCHE (0.43) BCHEC5AR1CASRACHE
SCHEMBL5137007 0.87 DRD2 (0.38) TP53BCHEC5AR1CASRGAA
SCHEMBL5070121 0.86 SMN1; SMN2 (0.41) TP53BCHEC5AR1GAASMN1; SMN2
SCHEMBL5135989 0.85 SMN1; SMN2 (0.39) TP53MAPTBCHEC5AR1GAA
SCHEMBL5069962 0.85 BCHE (0.45) BCHEC5AR1CASRTSHRACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed